Mapping and predicting mortality from systemic sclerosisMuriel Elhaï, Carlos Alberto von Mühlen, Serena Vettori et al.|Annals of the Rheumatic Diseases|2017Cited by 699
European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosisRobert Knobler, Thomas Krieg, Pia Moinzadeh et al.|Journal of the European Academy of Dermatology and Venereology|2017Cited by 115
Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experimentCosimo Bruni, Oliver Distler, Sebastian Heidenreich et al.|Lara D. Veeken|2022Cited by 12
POS0855 PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKINGCosimo Bruni, Oliver Distler, Sebastian Heidenreich et al.|Annals of the Rheumatic Diseases|2021Cited by 1